Article Top Ad
Reading Time: 2 minutes

LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Karyopharm’s new product XPOVIO(selinexor) a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

“Onco360 is excited to be selected as a specialty pharmacy provider for XPOVIO patients,” said Paul Jardina, President and CEO, Onco360. “The recent approval of XPOVIO unlocks a new treatment option for relapsed or refractory multiple myeloma patients who have failed previous lines of treatment. As a provider of this key treatment, Onco360 can support the highly specialized needs of relapsed or refractory multiple myeloma and their physicians across the states.”

Multiple myeloma is an incurable hematological malignancy involving plasma cells. Only 50 percent of patients diagnosed with multiple myeloma survive past five years following initial diagnosis. The National Cancer Institute estimates that in 2018, approximately 30,770 new patients were diagnosed with multiple myeloma in the U.S.1 Unfortunately, most multiple myeloma patients will relapse following the first complete remission and often require continuous treatment to prevent disease progression. Previously, there were no U.S. Food and Drug Administration (FDA)-approved products or regimens for patients with relapsed or refractory multiple myeloma who failed treatment with lenalidomide, pomalidomide, bortezomib, carfilzomib, and/or daratumumab.

XPOVIO is manufactured by Karyopharm Therapeutics, and was approved by the U.S. FDA on July 3, 2019 based on positive clinical trial results from the Phase IIb STORM Trial which demonstrated a 21% overall response rate in heavily-pretreated multiple myelmoma patients.2 XPOVIO is the first and only nuclear export inhibitor that blocks XPO1. For full prescribing information, visit

About Onco360® Oncology Pharmacy:

Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, ACHC- JCAHO-, and VIPPS-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit

1National Cancer Institute, Key Statistics for Multiple Myeloma (2019).



PharMerica Corporation / BrightSpring Health Services

Barnard Baker, Corporate PR & Communications


[email protected]